USA - NASDAQ:EVAX - US29970R3030 - ADR
We assign a fundamental rating of 2 out of 10 to EVAX. EVAX was compared to 534 industry peers in the Biotechnology industry. Both the profitability and financial health of EVAX have multiple concerns. EVAX is quite expensive at the moment. It does show a decent growth rate.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.34% | ||
| ROE | -192.34% | ||
| ROIC | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.73 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.23 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.42 | ||
| Quick Ratio | 3.42 |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:EVAX (10/30/2025, 11:21:55 AM)
5.82
+0.07 (+1.22%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 11.58 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.9 | ||
| P/tB | 5.9 | ||
| EV/EBITDA | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -53.34% | ||
| ROE | -192.34% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.73 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.42 | ||
| Quick Ratio | 3.42 | ||
| Altman-Z | -0.23 |
ChartMill assigns a fundamental rating of 2 / 10 to EVAX.
ChartMill assigns a valuation rating of 1 / 10 to EVAXION A/S (EVAX). This can be considered as Overvalued.
EVAXION A/S (EVAX) has a profitability rating of 0 / 10.
The financial health rating of EVAXION A/S (EVAX) is 3 / 10.
The Earnings per Share (EPS) of EVAXION A/S (EVAX) is expected to grow by 23.5% in the next year.